Characteristics and outcomes of 795 patients with renal cell cancer following hospitalization for acute myocardial infarction.

Authors

Kamleshun Ramphul

Kamleshun Ramphul

Independent Researcher, Triolet, Mauritius

Kamleshun Ramphul , Renuka Verma , Suma Sri Chennapragada , Mehndi Dandwani , Shivani Sharma , Alekhya Pagidipally , Fnu Arti , Shaheen Sombans , Sailaja Sanikommu , Yogeshwaree Ramphul , Prince Kwabla Pekyi-Boateng , Balkiranjit Kaur Dhillon , Stephanie G. Mejias , Vijay Kumar , Mohammed Elmahal , Petras Lohana

Organizations

Independent Researcher, Triolet, Mauritius, Raj Multispeciality Hospital, Mohali, India, LSU Health Shreveport, Shreveport, LA, Danbury Hospital, Yale Affiliated Hospitals Program, Danbury, CT, Louisiana State University Shreveport, Shreveport, LA, Kamineni Academy of Medical Sciences and Research Centre, NTRUHS, Hyderabad, India, MedStar Health, Columbia, MD, Bharati Vidyapeeth Univ Med College and Hosp, Hyderabad, India, Sri Manakula Vinayagar Med college and Hosp, Puducherry, India, SSRN Hospital, Pamplemousses, Mauritius, Department of Medicine, Korle-bu Teaching Hospital, Accra, Ghana, Accra, Ghana, Independent Researcher, Brampton, ON, Canada, Independent Researcher, Santo Domingo, Dominican Republic, University of Mississippi Medical Center, Mississippi, Khartoum North teaching Hospital, Khartoum, Sudan, Jacobi Medical Centre, Bronx, NY

Research Funding

No funding received
None.

Background: Renal cell cancer (RCC), as with many cancers, is associated with a hypercoagulable state as well as the potential risk of anemia that can lead to various cardio/cerebrovascular complications. Some of the treatments used in RCC like vascular endothelial growth factor (VEGF) inhibitors increase the thrombotic risk. Thus, the management of RCC patients following an episode of Acute Myocardial Infarction (AMI) can be more complex than that of the general population. We, therefore, conducted an in-depth analysis to study the characteristics and outcomes of AMI among RCC patients in the United States. Methods: We used the 2019 National Inpatient Sample (NIS), a yearly set of hospitalization records from the United States. Patients with a primary diagnosis of AMI and a diagnosis of RCC were identified. We excluded all patients below the age of 18 and those with other malignancies. Multiple patient characteristics were compared via Chi-Square tests. We also compared the odds of requiring Coronary artery bypass graft surgery (CABG) and Percutaneous coronary intervention (PCI) among the two groups. The overall mortality rate and adjusted odds ratios were estimated. Results: Our study found 633410 cases of AMI among adults in the United States in 2019. Among them, 795 (0.1%) had a diagnosis of RCC. A higher number of RCC patients were Male (75.5% vs. 62.7%, p < 0.01), racially classified as White (77.1% vs. 73.0%, p < 0.01), aged 60 or more (88.7% vs. 69.8%, p < 0.01), covered by Medicare (72.3% vs. 56.1%, p < 0.01), had hypertension (66.7% vs. 82.7%, p < 0.01), were diabetics (45.9% vs. 41.4%, p < 0.01) or had anemia (42.1% vs. 22.1%, p < 0.01). A lower percentage of RCC patients underwent various procedures following their AMI, as only 6.3% underwent CABG (vs. 7.5% in the non-RCC group), and 27.6% (vs. 45.8% in the non-RCC group) underwent PCI. Patients with RCC were also older (71.62 years vs. 66.64 years, p < 0.01), had a longer hospitalization (5.51 days vs.4.34 days, p < 0.01), which was also associated with a more expensive mean hospital charge ($114572.98 vs. $106241.24). Unfortunately, we also found that the presence of RCC among AMI patients was also linked with a higher odds ratio of mortality (7.5% vs. 4.4%, aOR 1.643, 95% CI 1.249- 2.160, p < 0.01). Conclusions: Our study confirms various differences in patient characteristics among AMI cases with and without RCC. While fewer RCC patients underwent procedures such as CABG or PCI, they experienced a less favorable outcome, including a longer and more costly stay and higher odds of in-hospital death. It is thus vital to screen RCC patients for potential risk factors for AMI, promote primary and secondary prevention measures, and improve hospitalization protocols to identify potential complications.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e16516)

DOI

10.1200/JCO.2023.41.16_suppl.e16516

Abstract #

e16516

Abstract Disclosures

Similar Abstracts

First Author: Maxwell Sandberg

First Author: Franklin Liu

First Author: Arun Kumar

Abstract

2023 ASCO Annual Meeting

Mortality among oncology patients with multiple unplanned hospital admissions.

First Author: Thomas J Roberts